Antibiotics in Cell Culture: When to Use, When to Avoid, and How to Choose

Why Are Antibiotics Used in Cell Culture?

A single contaminated flask can erase months of work. That reality drives the nearly universal habit of adding antibiotics to every culture dish. Yet the practice splits cleanly into two distinct goals: preventing contamination in routine maintenance and selecting genetically modified cells after transfection. Understanding that split is the first step toward using antibiotics intelligently.

Preventive use aims to suppress bacteria, fungi, or mycoplasma that might enter through human error or aerosol exposure. Standard lab practice relies on penicillin-streptomycin (PenStrep) or gentamicin added to complete growth medium. These agents are intended as a safety net, not a substitute for aseptic technique. Selective use, in contrast, exploits resistance genes introduced into the genome. A transfected population is exposed to a cytotoxic antibiotic—puromycin, hygromycin B, or blasticidin, for example—so that only cells carrying the corresponding resistance cassette survive. The exposure is typically 3–14 days, after which the antibiotic may be removed or reduced.

This distinction matters because the risks and downstream consequences differ. The rest of this article unpacks when to use which, what the data say about hidden effects, and how to move toward antibiotic-free culture with confidence.

Common Antibiotics and Their Mechanisms of Action

Cell culture antibiotics fall into four mechanistic classes: disruption of cell wall synthesis, inhibition of protein synthesis, interference with nucleic acid synthesis, and destabilization of membrane integrity. Each class targets a distinct vulnerability, and the choice should match the contaminant you aim to control—or the resistance gene you have introduced.

Below is a practical reference table that captures the most frequently used agents. Concentrations are starting points; actual working values must be titrated for each cell type (see toxicity testing section).

When selecting an antibiotic for stable line generation, always match the drug to the resistance cassette on your vector. Using the wrong agent simply kills all cells. In the next section, we look at what happens even when the “right” preventive antibiotics are used—and why a growing body of evidence suggests caution.

The Evidence Against Routine Antibiotic Use

For decades, adding PenStrep to medium was as automatic as changing pipette tips. Then a landmark 2017 study in Scientific Reports revealed that routine antibiotic supplementation tangibly rewires cellular programs. The findings were not subtle.

Investigators cultured HepG2 liver cells—a workhorse for drug metabolism and toxicology studies—in medium with or without penicillin-streptomycin. RNA‑seq identified 209 genes differentially expressed between the two conditions. ChIP‑seq for the active enhancer mark H3K27ac uncovered 9,514 peaks that changed with antibiotic exposure. Pathway analysis flagged xenobiotic metabolism signaling and PXR/RXR activation as significantly enriched, meaning the very pathways a pharmacologist might study were being perturbed by the preventive antibiotic itself.

This isn’t just a liver‑cell story. Subsequent reports show that antibiotics can shift epithelial‑mesenchymal transition markers in breast cancer lines, alter cytokine secretion in immune cells, and affect differentiation kinetics in progenitor populations. Primary cells and stem cells—with their finer regulatory balance—often show greater sensitivity than immortalized lines. The practical takeaway: if your endpoint involves gene expression, metabolism, or drug response, the blanket use of antibiotics is a variable you cannot afford to ignore.

Even when contamination is the primary concern, antibiotics can mask low‑level infections. Mycoplasma, for instance, may persist at reduced titers, creating a chronic, subclinical state that still alters host cell behavior while evading detection. The cure becomes a confounder.

How to Choose the Right Antibiotic for Your Cell Type

No single antibiotic—or combination—works across all cell models. The decision tree should consider cell origin, proliferative capacity, and the specific contaminant (or selection pressure) you face.

• Immortalized cell lines (HEK293, HeLa, HepG2) tolerate most common preventive antibiotics at standard concentrations. For selection, puromycin at 1–3 µg/mL works quickly; hygromycin B at 100–200 µg/mL is a reliable alternative. Always run a kill curve, as sensitivities vary even within a line.
• Primary cells (hepatocytes, keratinocytes, endothelial cells) are frequently more vulnerable. Puromycin, in particular, can induce rapid apoptosis. Gentamicin or PenStrep at the low end of the range (e.g., 50 µg/mL each) is safer for short‑term use. For selection, blasticidin or hygromycin B often shows a better therapeutic window, though concentrations must be titrated downward.
• Stem cells and iPSCs demand the strictest aseptic technique and generally antibiotic‑free maintenance. If a transient preventive is unavoidable—for example, during thawing—use the lowest possible gentamicin concentration and remove it by the first passage. Antibiotic‑free culture is the standard for differentiation protocols, as even brief exposure can shift lineage commitment.
• Immune cells (T cells, NK cells, macrophages) respond to contamination differently and may be affected by antibiotics that modulate cytokine production. PenStrep is frequently used in T‑cell expansion without overt toxicity, but mycoplasma‑specific regimens like Plasmocin should be reserved for confirmed outbreaks, not prophylaxis.

Beyond cell type, consider the medium formulation. Penicillin loses activity at alkaline pH, so if you buffer with high bicarbonate and 5% CO₂, the effective concentration may drift. Tetracycline derivatives, including doxycycline used in inducible systems, chelate divalent cations present in DMEM or RPMI, reducing free drug levels. Serum proteins bind some antibiotics substantially; in 10% FBS, free gentamicin can drop by 20–30%. Whenever possible, prepare antibiotic‑containing medium fresh and filter it through a sterile syringe filter to remove any particulates before adding to cells.

Antibiotic Toxicity Testing: A Step‑by‑Step Protocol

Every new cell‑antibiotic combination demands a kill curve. The goal is to identify the concentration that kills untransduced or non‑transfected cells without causing collateral damage to the target population. The workflow below uses a 96‑well format and a metabolic activity assay.

1. Seed cells at a density that reaches 70–80% confluence after 24 hours. Use the same medium and serum batch planned for the actual experiment.
2. Prepare a 2‑fold dilution series of the antibiotic in at least triplicate, spanning 0–10× the expected working concentration. Include a no‑antibiotic control.
3. Aspirate spent medium and add the antibiotic‑containing medium. Incubate at 37 °C, 5% CO₂ for 48–72 hours, depending on the doubling time of the line.
4. Assess viability using a Cell Counting Kit‑8 (CCK‑8) or MTT assay. Follow the manufacturer’s protocol; for CCK‑8, incubate 1–3 hours and measure absorbance at 450 nm.
5. Calculate viability as (OD_treated – OD_blank) / (OD_control – OD_blank) × 100. Plot a dose‑response curve and determine IC₁₀ and IC₅₀.

Select a working concentration at or just below the IC₁₀—the concentration that yields ≥90% viability. This minimal‑toxicity dose preserves normal physiology while eliminating sensitive non‑transfected cells. An illustrative dataset is shown below.

In this example, 0.5 µg/mL is near the IC₁₀ and could serve as a maintenance dose for a stable line, while selection would require ≥1 µg/mL. Re‑test the curve whenever you change serum lot or medium supplier; even modest formulation shifts can swing the IC₅₀ by two‑fold.

Transitioning to Antibiotic‑Free Culture

Moving to antibiotic‑free conditions isn’t simply about omitting the drug. It requires verification that your stock is truly free of hidden contaminants and that aseptic habits are robust enough to keep it that way. The following staged protocol, aligned with ATCC and ECACC recommendations, minimizes risk while you build confidence.

1. Wean or withdraw immediately? For most lines, you can remove antibiotics in a single step. If you have maintained cultures with antibiotics for many passages, a two‑stage reduction (half‑strength for one passage, then zero) can ease the transition.
2. Culture the cells without antibiotics for at least three passages (roughly 2–3 weeks). Observe daily for any sudden pH drop, turbidity, or morphological drift.
3. After the third passage, draw a sample for mycoplasma testing by qPCR or Hoechst DNA staining. Also plate a small aliquot of conditioned medium onto bacterial and fungal agar and incubate at 30 °C and 37 °C for 5–7 days to detect low‑level contamination that visual inspection misses.
4. If all tests come back negative, you can declare the culture antibiotic‑free. Continue monthly mycoplasma surveillance and, critically, reinforce aseptic technique. Use sterile single‑use consumables such as tissue culture plates and pre‑sterilized media bottles; work only in a certified biosafety cabinet; and never share media between lines.
5. Reserve antibiotics for genuine emergencies, not daily prophylaxis. If a contamination event occurs, treat the affected culture isolate, verify clearance, and discard the treated cells as soon as backup stocks are available.

A laboratory that commits to antibiotic‑free culture often discovers that contamination rates drop simply because technique improves when the safety net is gone. The payoff is cleaner data and greater confidence that the biology you measure belongs to your cells—not to an unintended chemical perturbation.